Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7117443 | 0.82 | EPHX2 (0.62) | EPHX2BACE1BACE2MEN1KMT2A | |
| SCHEMBL7984241 | 0.80 | HIF1A (0.38) | MEN1KMT2AKCNK3KCNK9HIF1A | |
| SCHEMBL7130669 | 0.79 | EPHX2 (0.37) | EPHX2MEN1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL6962792 | 0.78 | KCNK3 (0.54) | MEN1KMT2AKCNK3KCNK9SMN1; SMN2 | |
| SCHEMBL7128091 | 0.78 | EPHX2 (0.50) | EPHX2BACE1BACE2 | |
| SCHEMBL7126929 | 0.77 | EPHX2 (0.55) | EPHX2BACE1BACE2MEN1KMT2A | |
| SCHEMBL4741893 | 0.71 | EPHX2 (0.71) | EPHX2BACE1BACE2MEN1KMT2A | |
| SCHEMBL7115895 | 0.71 | EPHX2 (0.71) | EPHX2BACE1BACE2MEN1KMT2A | |
| SCHEMBL15499631 | 0.71 | NPC1 (0.50) | MEN1KMT2AKCNK3KCNK9SMN1; SMN2 | |
| SCHEMBL7084928 | 0.71 | KCNK3 (0.58) | EPHX2MEN1KMT2AKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | EPHX2 354/4885BACE1 1539/4885BACE2 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.